CTHRSSVVC Peptide as a Possible Early Molecular Imaging Target for Atherosclerosis
Authors:
- Rosemeire A. SilvaRSRosemeire A. Silva
- Ricardo J. GiordanoRGRicardo J. Giordano
- Paulo S. GutierrezPGPaulo S. Gutierrez
- Viviane Z. RochaVRViviane Z. Rocha
- Martina RudnickiMRMartina Rudnicki
- Patrick KeePKPatrick Kee
- Dulcinéia S. P. AbdallaDADulcinéia S. P. Abdalla
- Pedro Puech-LeãoPPPedro Puech-Leão
- Bruno CaramelliBCBruno Caramelli
- Wadih ArapWAWadih Arap
- Renata PasqualiniRPRenata Pasqualini
- José C. MeneghettiJMJosé C. Meneghetti
Open Access
- 24 August 2016
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (9) , 1383
Abstract
The purpose of our work was to select phages displaying peptides capable of binding to vascular markers present in human atheroma, and validate their capacity to target the vascular markers in vitro and in low-density lipoprotein receptor knockout (LDLr−/−) mouse model of atherosclerosis. By peptide fingerprinting on human atherosclerotic tissues, we selected and isolated four different peptides sequences, which bind to atherosclerotic lesions and share significant similarity to known human proteins with prominent roles in atherosclerosis. The CTHRSSVVC-phage peptide displayed the strongest reactivity with human carotid atherosclerotic lesions (p < 0.05), when compared to tissues from normal carotid arteries. This peptide sequence shares similarity to a sequence present in the fifth scavenger receptor cysteine-rich (SRCR) domain of CD163, which appeared to bind to CD163, and subsequently, was internalized by macrophages. Moreover, the CTHRSSVVC-phage targets atherosclerotic lesions of a low-density lipoprotein receptor knockout (LDLr−/−) mouse model of atherosclerosis in vivo to High-Fat diet group versus Control group. Tetraazacyclododecane-1,4,7,10-tetraacetic acid-CTHRSSVVC peptide (DOTA-CTHRSSVVC) was synthesized and labeled with 111InCl3 in >95% yield as determined by high performance liquid chromatography (HPLC), to validate the binding of the peptide in atherosclerotic plaque specimens. The results supported our hypothesis that CTHRSSVVC peptide has a remarkable sequence for the development of theranostics approaches in the treatment of atherosclerosis and other diseases.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2004/02721-8)
This publication has 38 references indexed in Scilit:
- Combinatorial vascular targeting in translational medicineProteomics – Clinical Applications, 2010
- Peripheral Artery Disease Is Associated With a High CD163/TWEAK Plasma RatioArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- From combinatorial peptide selection to drug prototype (I): Targeting the vascular endothelial growth factor receptor pathwayProceedings of the National Academy of Sciences, 2010
- Is PlGF a plaque growth factor?Cardiovascular Research, 2010
- Hemoglobin and Heme Scavenger ReceptorsAntioxidants & Redox Signaling, 2010
- Combinatorial Ligand-directed Lung TargetingProceedings of the American Thoracic Society, 2009
- Coronary Intraplaque Hemorrhage Evokes a Novel Atheroprotective Macrophage PhenotypeThe American Journal of Pathology, 2009
- Targeted Induction of Lung Endothelial Cell Apoptosis Causes Emphysema-like Changes in the MouseJournal of Biological Chemistry, 2008
- Identification of atherosclerosis-associated conformational heat shock protein 60 epitopes by phage display and structural alignmentAtherosclerosis, 2007
- Combinatorial Screenings in PatientsCancer Research, 2004